These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

208 related items for PubMed ID: 30808100

  • 21. Lung cancer in 2016: immunotherapy comes of age.
    Mitchell PL, John T.
    Lancet Respir Med; 2016 Dec; 4(12):947-949. PubMed ID: 27890503
    [No Abstract] [Full Text] [Related]

  • 22. Bullous pemphigoid induced by pembrolizumab in a patient with non-small-cell lung cancer who achieved durable complete response despite treatment cessation and long-term corticosteroid administration: A case report.
    Muto Y, Namikawa K, Fujiwara Y, Mori T, Nakano E, Takahashi A, Yamazaki N.
    J Dermatol; 2020 Jan; 47(1):e9-e11. PubMed ID: 31674068
    [No Abstract] [Full Text] [Related]

  • 23. PD-1 Blockade-Induced Pruritus Treated with a Mu-Opioid Receptor Antagonist.
    Kwatra SG, Ständer S, Kang H.
    N Engl J Med; 2018 Oct 18; 379(16):1578-1579. PubMed ID: 30332571
    [No Abstract] [Full Text] [Related]

  • 24. Pembrolizumab for classical Hodgkin's lymphoma.
    Burki TK.
    Lancet Oncol; 2016 Aug 18; 17(8):e324. PubMed ID: 27397043
    [No Abstract] [Full Text] [Related]

  • 25. Therapeutic Exposure and Successful Response to Pembrolizumab in a Patient With Non-Small-Cell Lung Cancer Despite Significant Renal Loss Due to Paraneoplastic Nephrotic Syndrome.
    Jansen AME, Sriram JD, Pluim D, Maas RJH, van Groningen H, Piet B, Ter Heine R.
    Clin Lung Cancer; 2021 Mar 18; 22(2):e220-e223. PubMed ID: 33189593
    [No Abstract] [Full Text] [Related]

  • 26. Development of Thyroid Carcinoma During Treatment With Pembrolizumab in a Lung Cancer Patient.
    Gorospe L, García-Gómez-Muriel I, Pian-Arias HG, Gómez-Ramírez J, Rioja-Martín ME, Olmedo-García ME, Garrido-López P, Muñoz-Molina GM, Mezquita L.
    Ann Thorac Surg; 2020 Jun 18; 109(6):e397-e399. PubMed ID: 31846639
    [Abstract] [Full Text] [Related]

  • 27. Thoracic Imaging of Non-Small Cell Lung Cancer Treated With Anti-programmed Death Receptor-1 Therapy.
    Hammer M, Bagley S, Aggarwal C, Bauml J, Nachiappan AC, Simone CB, Langer C, Katz SI.
    Curr Probl Diagn Radiol; 2019 Jun 18; 48(2):142-147. PubMed ID: 29573843
    [Abstract] [Full Text] [Related]

  • 28. Sintilimab-Induced Autoimmune Diabetes in a Patient With the Anti-tumor Effect of Partial Regression.
    Wen L, Zou X, Chen Y, Bai X, Liang T.
    Front Immunol; 2020 Jun 18; 11():2076. PubMed ID: 32973816
    [Abstract] [Full Text] [Related]

  • 29. Successful Treatment of Non-small-cell Lung Cancer with Atezolizumab Following Tubulointerstitial Nephritis Due to Pembrolizumab.
    Taki T, Oda N, Fujioka Y, Mitani R, Tokura T, Takata I, Oshiro Y, Takigawa N.
    Intern Med; 2020 Jul 01; 59(13):1639-1642. PubMed ID: 32269191
    [Abstract] [Full Text] [Related]

  • 30. Histologic Transformation in a Patient with Lung Cancer Treated with Chemotherapy and Pembrolizumab.
    Hsu CL, Chen KY, Kuo SW, Chang YL.
    J Thorac Oncol; 2017 Jun 01; 12(6):e75-e76. PubMed ID: 28532567
    [No Abstract] [Full Text] [Related]

  • 31. Esophagitis in Non-Small Cell Lung Carcinoma Treatment Caused by Pembrolizumab.
    Yoshida S, Miyamoto S, Naruse H, Ito J, Kinosita K, Kudo T, Hatanaka K, Yamamoto Y, Sakamoto N.
    Am J Gastroenterol; 2020 Jan 01; 115(1):13. PubMed ID: 31356230
    [No Abstract] [Full Text] [Related]

  • 32. Pembrolizumab as first-line therapy in programmed death ligand 1-positive advanced lung cancer: Is it as effective as we think it is?
    Goldstein DA, Bilal U, Prasad V.
    Cancer; 2017 Oct 15; 123(20):3872-3874. PubMed ID: 28662268
    [No Abstract] [Full Text] [Related]

  • 33. Retreatment with pembrolizumab in advanced non-small cell lung cancer patients previously treated with nivolumab: emerging reports of 12 cases.
    Fujita K, Uchida N, Kanai O, Okamura M, Nakatani K, Mio T.
    Cancer Chemother Pharmacol; 2018 Jun 15; 81(6):1105-1109. PubMed ID: 29675747
    [Abstract] [Full Text] [Related]

  • 34. Three cases of immune cholangitis related to anti-programmed cell death and programmed cell death ligand agents for the treatment of non-small cell lung cancer.
    Fouchard M, Jantzem H, Quere G, Descourt R, Robinet G, Poureau PG.
    Eur J Cancer; 2019 Jul 15; 115():107-110. PubMed ID: 31132740
    [No Abstract] [Full Text] [Related]

  • 35. Complete and Sustained Response of Brain Metastases to Programmed Death 1 Antibody Monotherapy in Treatment-naive Programmed Death Ligand 1-Positive Lung Cancer.
    Varkaris A, Sehgal K, Rangachari D, Costa DB.
    J Thorac Oncol; 2019 Feb 15; 14(2):e34-e36. PubMed ID: 30683297
    [No Abstract] [Full Text] [Related]

  • 36. Life threatening pembrolizumabinduced myositis in a patient treated for advanced adenocarcinoma of the lung.
    Robinson SD, Lai C, Hotton G, Anand G.
    Acute Med; 2019 Feb 15; 18(3):197-199. PubMed ID: 31536059
    [Abstract] [Full Text] [Related]

  • 37. Pembrolizumab KEYNOTE-001: an adaptive study leading to accelerated approval for two indications and a companion diagnostic.
    Kang SP, Gergich K, Lubiniecki GM, de Alwis DP, Chen C, Tice MAB, Rubin EH.
    Ann Oncol; 2017 Jun 01; 28(6):1388-1398. PubMed ID: 30052728
    [No Abstract] [Full Text] [Related]

  • 38.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 39. Multiple sclerosis associated with pembrolizumab in a patient with non-small cell lung cancer.
    Romeo MAL, Garassino MC, Moiola L, Galli G, Comi G, Martinelli V, Filippi M.
    J Neurol; 2019 Dec 01; 266(12):3163-3166. PubMed ID: 31586260
    [No Abstract] [Full Text] [Related]

  • 40. Tracheoesophageal Fistula Caused by Successful Response to Pembrolizumab in a Patient With Squamous Cell Lung Cancer.
    Wang H, Zhang L, Liu W.
    J Thorac Oncol; 2019 Jul 01; 14(7):e141-e143. PubMed ID: 31235036
    [No Abstract] [Full Text] [Related]

    Page: [Previous] [Next] [New Search]
    of 11.